Norursodeoxycholic Acid (Highly Pure)

Norursodeoxycholic Acid (Highly Pure)
Catalog number: B2012601
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 1 mg
Molecular Weight or Concentration: 378.6 g/mol
Supplied as: Lyophilized Powder
Applications: molecular tool for various biochemical applications
Storage: -20°C
Keywords: norUDCA, 24-Norursodeoxycholic Acid, Nourcholic Acid
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Trauner M, Halilbasic E, Kazemi-Shirazi L, Kienbacher C, Staufer K, Traussnigg S, Hofer H. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies Dig Dis. 2014;32(5):631-6.
2: Trauner M, Halilbasic E, Claudel T, Steinacher D, Fuchs C, Moustafa T, Pollheimer M, Krones E, Kienbacher C, Traussnigg S, Kazemi-Shirazi L, Munda P, Hofer H, Fickert P, Paumgartner G. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders Dig Dis. 2015;33(3):433-9.
3: Stättermayer AF, Halilbasic E, Wrba F, Ferenci P, Trauner M. Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults J Hepatol. 2020 Sep;73(3):651-663.
4: Koopman BJ, Wolthers BG, van der Molen JC, Nagel GT, Kruizinga W. Abnormal urinary bile acids in a patient suffering from cerebrotendinous xanthomatosis during oral administration of ursodeoxycholic acid Biochim Biophys Acta. 1987 Feb 14;917(2):238-46.
5: Halilbasic E, Fuchs C, Hofer H, Paumgartner G, Trauner M. Therapy of Primary Sclerosing Cholangitis–Today and Tomorrow Dig Dis. 2015;33 Suppl 2:149-63.
6: Ðanić M, Stanimirov B, Pavlović N, Goločorbin-Kon S, Al-Salami H, Stankov K, Mikov M. Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome Front Pharmacol. 2018 Dec 3;9:1382.
7: Sedki M, Levy C. Update in the Care and Management of Patients with Primary Sclerosing Cholangitis Curr Gastroenterol Rep. 2018 Jun 9;20(7):29.
8: Steinacher D, Claudel T, Trauner M. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease Dig Dis. 2017;35(3):282-287.
9: Nevens F, Trauner M, Manns MP. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases(†) J Hepatol. 2022 Oct 20:S0168-8278(22)03143-9.
10: Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodríguez-Tajes S, Genescà J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease J Hepatol. 2022 Apr;76(4):812-821.

Products Related to Norursodeoxycholic Acid (Highly Pure) can be found at Chemicals